tirzepetide vs semaglutide Tirzepatide Dose-Dependent Efficacy of Tirzepatide vs

Fox Foundation to present an

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

These results suggest chronic treatment with GLP-1R agonists could lead to proliferation/chronic activation of PSCs, which may lead to important effects in the pancreas.

Mounjaro and sun exposure: discover essential sun safety guidance for patients taking tirzepatide, including protection strategies, managing side effects in warm weather, and when to seek medical advice for type 2 diabetes treatment.

Holistic Metabolic Support

Finally, we presented our insights on clinical concerns such as appropriate trial endpoints, management of comorbidities, and future developments